Accuray Incorporated

Accuray Incorporated designs and sells radiosurgery and radiation therapy systems for tumor treatment globally. The company offers the CyberKnife System for treating tumors outside the brain. It also provides the TomoTherapy System, including the Radixact System, for integrated treatment planning and delivery. Accuray offers post-contract customer support, installation, training, and professional services. Products are marketed directly to customers through a sales organization or indirectly through agents and distributors. The company was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Overview

Sector

Medical Devices

Target Price

0.0 USD

Current Price

1.2 USD

Potential

-100%

Strengths

Price to book ratio (2.71) is lower than the sector mean (13.90).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (13.36) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (2.97%).
EV/EBIT (100.00) is significantly higher than the sector mean.
EBITDA Margin (1.74%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	29.1
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	13.4